Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Hip Health and Mobility
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Rehabilitation Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Lungs

Lungs

Recruiting

IMPACT

The purpose of this study is to build a tool to support medical decision-making and the integration of a validated clinical-prediction model into routine care for individuals with chronic obstructive pulmonary disease (COPD).

Status
Recruiting
Principal Investigator
Mohsen Sadatsafavi
Body Locations and Systems
Lungs and Breathing
COPD

Canadian Asthma Text Messaging Study

The purpose of this study is to understand asthmatic patients' knowledge, perceptions and viewpoints about using a telehealth approach to manage their asthma conditions.

Status
Recruiting
Principal Investigator
Mark FitzGerald
Body Locations and Systems
Lungs and Breathing
Asthma
Age
21 and above

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma

The purpose of this study is to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.

Status
Recruiting
Principal Investigator
Céline Bergeron
Body Locations and Systems
Lungs and Breathing
Asthma
Area
Vancouver
Age
12-80

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension (REBUILD)

The purpose of this study is to assess the safety and efficacy of pulsed inhaled nitric oxide versus placebo in subjects at risk for pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy.

Status
Recruiting
Principal Investigator
Nasreen Khalil
Body Locations and Systems
Pulmonary Fibrosis
Pulmonary Hypertension
Area
Vancouver
Age
18 - 80

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension

The purpose of this study is determine if a fixed-dose combination of the drugs macitentan and tadalafil is more effective than therapy with macitentan or tadalafil alone to treat pulmonary arterial hypertension.

Status
Recruiting
Principal Investigator
John Swiston
Body Locations and Systems
Pulmonary Hypertension
Area
Vancouver
Age
18 - 75

Lung health benefits of e-cigarette cessation

The purpose of this study is to determine the lung and immune function benefits of stopping vaping for 72 hours in young adults who use e-cigarettes containing nicotine. The study also aims to determine if telling participants of their own personalized changes to their lung and immune function following the 72 hour abstinence period affects their motivation in quitting vaping.

Status
Recruiting
Principal Investigator
Christopher Carlsten
Body Locations and Systems
Smoking Cessation
Area
Vancouver
Age
19 - 35

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

The purpose of this study is to test the safety and efficacy of an inhaled medication (CSJ117) compared with a placebo for improving lung function in patients with inadequate control of moderate to severe asthma.

Status
Recruiting
Principal Investigator
Mark FitzGerald
Body Locations and Systems
Asthma
Area
Vancouver
Age
18 - 75

A Study to Evaluate the Efficacy and Safety of Dupilumab in Participants With Allergic Bronchopulmonary Aspergillosis

The purpose of this study is to determine if dupilumab is effective and safe in decreasing episodes of severe breathing difficulties in patients with allergic bronchopulmonary aspergillosis (ABPA).

Status
Recruiting
Principal Investigator
Mark FitzGerald
Body Locations and Systems
Lungs
Area
Vancouver
Age
18 and above

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or International Treatment (SELECT)

The purpose of this study aims to assess the efficacy and safety of selexipag in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).

Status
Recruiting
Principal Investigator
Nathan Brunner
Body Locations and Systems
Heart
Lungs
Area
Vancouver
Age
18 - 85

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory pharmacodynamics (PD) of two treatment doses of CC-90001, 200 mg and 400 mg, compared with placebo, when delivered once daily per os (PO) in subjects with idiopathic pulmonary fibrosis (IPF). This study is designed to assess response to treatment by using measures of lung function, disease progression, fibrosis on radiography, and patient-reported outcomes. It will also assess dose response

Status
Recruiting
Principal Investigator
Nasreen Khalil
Body Locations and Systems
Pulmonary Fibrosis
Area
Vancouver
Age
40 years and above

Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics (ARIA)

This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.

Status
Recruiting
Principal Investigator
Mark FitzGerald
Body Locations and Systems
Asthma
Area
Vancouver
Age
18-65

International Lung Screen Trial (ILST)

People who may be at increased risk of lung cancer due to age and smoking history will be invited to participate in this international study to determine the best way of using computed tomography (CT) of the chest to screen for early lung cancer. Overseas data show that CT screening (screening tests can find diseases early, when they're easier to treat) can reduce deaths from lung cancer and this study will help determine who is most likely benefit from screening.

Status
Recruiting
Principal Investigator
Stephen Lam
Body Locations and Systems
Lung Cancer
Area
Vancouver
Age
55-80

Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

The purpose of this study is to evaluate the long-term safety, efficacy and tolerability of dupilumab in patients with asthma who participated in a previous dupilumab asthma study.

 

 

Status
Recruiting
Principal Investigator
Mark FitzGerald
Body Locations and Systems
Asthma
Area
Vancouver
Age
12 and above

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

The objectives of this trial are primarily to evaluate the efficacy and safety of BI 655066 as compared to placebo over a 24-week treatment period in severe asthma patients. The primary endpoint is time to first asthma worsening during the planned 24 week treatment period for active vs. placebo treated patients on top of standard of care therapy. Upon demonstration of a meaningful clinical response, another important objective is the identification of biomarkers that can be used to target patients who will likely respond to treatment with BI 655066.
 

Status
Recruiting
Principal Investigator
Mark FitzGerald
Body Locations and Systems
Asthma
Area
Vancouver
Age
18-75

Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure (ADVENT-HF)

Sleep Apnea (SA) is a disorder that causes pauses in breathing during sleep that expose the heart to oxygen deprivation. It is common in patients with heart failure (HF) where it is associated with increased risk of hospitalizations and death. It is not known however whether treating SA reduces these risks. This study is looking at whether a respiratory device known as Adaptive Servo Ventilation (ASV) can reduce the rate of cardiovascular hospitalizations and death in subjects with HF and SA.

Status
Recruiting
Principal Investigator
John Fleetham
Body Locations and Systems
Heart Failure
Sleep Apnea Syndromes
Area
Vancouver
Age
18 and above

Closed for Recruitment

Public engagement of wildfire smoke exposure and public health messages in BC

The purpose of this study is to determine if BC residents receive, understand and implement public health messages related to wildfire smoke exposures, and to better understand the reach of these messages and identify opportunities for future improvement.

Status
Closed for Recruitment
Principal Investigator
Christopher Carlsten
Body Locations and Systems
Lungs
Area
Vancouver
Age
18 and above

Care during COVID-19 survey

The purpose of this study is to understand how patients with asthma and COPD have been affected by the changes to the health care system as a result of the COVID-19 pandemic.

Status
Closed for Recruitment
Principal Investigator
Christopher Carlsten
Body Locations and Systems
Asthma
COPD
Area
Vancouver
Age
18 and above

Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER (RANGER)

This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.

Status
Closed for Recruitment
Principal Investigator
John Swiston
Body Locations and Systems
Pulmonary Hypertension
Area
Vancouver
Age
18-85 years

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy (REPLACE)

To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients

Status
Closed for Recruitment
Principal Investigator
John Swiston
Body Locations and Systems
Pulmonary Hypertension
Area
Vancouver
Age
18-75 years

Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST

This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with connective tissue disease-associated pulmonary arterial hypertension to determine the recommended dose range and evaluate the change from baseline in 6-minute walk distance (6MWD) following 24 weeks of study participation.

Status
Closed for Recruitment
Principal Investigator
John Swiston
Body Locations and Systems
Pulmonary Hypertension
Area
Vancouver
Age
18-75

Pagination

  • Current page 1
  • Page 2
  • Next page
Subscribe to Lungs

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy